Identifying Lymphoma Survivors at Higher Risk for LVSD, Heart Failure
Researchers may have found a way to identify adult lymphoma survivors at increased risk for left ventricular systolic dysfunction.
Researchers may have found a way to identify adult lymphoma survivors at increased risk for left ventricular systolic dysfunction (LVSD), which can serve as a basis for targeted surveillance, according to an article published online ahead of print in the Journal of Clinical Oncology.
Their study's goal was to determine the prevalence of symptomatic and asymptomatic LVSD in lymphoma survivors (LSs) following autologous hematopoietic stem-cell transplantation (auto-HCT) and to identify risk factors in this population.
A total of 274 LSs were examined; 62% were men, the mean age was 56 (standard deviation±12 years), and mean follow-up time from lymphoma diagnosis was 13±6 years. Mean cumulative doxorubicin dose was 316±111 mg/m2, and 35% of LSs had received additional radiation therapy involving the heart.
LVSD was found in 15.7% of the LSs (5.1% asymptomatic). Severe heart failure was rare, and occurred in 1.8%, which was less than previously reported in this patient population. Compared with controls, LSs had a substantially increased LVSD risk (odds ratio 6.6; 95% CI, 2.5, 17.6; P<0.001).
A doxorubicin dose greater than or equal to 300 mg/m2 and cardiac radiation therapy dose greater than 30 Gy were independent risk factors for LVSD.